Emcure Pharmaceuticals is entering a phase where earnings are growing faster than revenue, supported by improving operating efficiency and scale. Between FY24 and FY26, PAT grew significantly faster than the topline, while margins also expanded. The key question is whether this operating leverage can continue as the company scales its domestic and international businesses.
Emcure Pharmaceuticals was recently trading around ₹1,938 per share, with a market capitalization of roughly ₹36,757 crore and a trailing P/E of around 36x. The stock’s 52-week range was approximately ₹1,300–₹2,101.
Earnings Are Outpacing Revenue
The difference between revenue and earnings growth is the starting point of the story. Emcure’s revenue increased from ₹6,658 crore in FY24 to ₹9,204 crore in FY26, while EBITDA rose from ₹1,230 crore to ₹1,789 crore. PAT increased from ₹528 crore to ₹941 crore over the same period.
This means the company is not relying only on higher sales to grow profits. Its EBITDA margin increased by 90 basis points to 19.4%, while PAT margin expanded from 7.9% to 10.2%. The improvement suggests that a growing portion of incremental revenue is reaching the bottom line as the company’s scale increases.
Q1 Shows Operating Leverage
The trend continued in Q1 FY27. Revenue from operations increased 22.8% YoY to ₹2,580 crore, while EBITDA grew 25.8% to ₹508 crore. EBITDA margin consequently improved to 19.7% from 19.2%, with management attributing the improvement to scale, productivity initiatives and operating leverage.
Reported PAT increased 36.2% to ₹292 crore, while PAT margin expanded by 110 basis points, growing from 10.2% in Q1 FY26 to 11.3% in Q1 FY27. The difference between revenue and EBITDA growth is particularly relevant because it indicates that Emcure is currently absorbing a greater portion of its fixed operating costs as the business gets larger.
International Business Is Driving Growth
The international business has become an increasingly important growth engine. In Q1 FY27, international revenue increased 34.2% to ₹1,485 crore, compared with 10.2% growth in India to ₹1,095 crore. Europe grew 32.8%, Canada 24.6% and Rest of World 44.8%. Management attributed the international performance to base-business expansion, new launches and currency tailwinds.
This faster international growth is also changing Emcure’s revenue mix. In FY26, the company generated 56% of revenue internationally and 44% domestically.
However, stronger international contribution is not automatically margin-accretive. The CFO noted that Q1 gross margin declined to 58.4%, primarily because of the higher export and geographic mix. Management said it continues to target procurement and cost-of-goods improvements, but expects gross margin to remain around the 59–60% range if international growth continues to outperform.
Domestic Productivity Is Improving
Emcure’s domestic business is showing a different growth lever: productivity. FY26 domestic revenue reached ₹4,027 crore, up 10% YoY, while the company’s chronic mix increased to more than 60%, compared with around 46% in FY23. The company has also expanded its field force to more than 4,000 employees.
The number of brands generating more than ₹500 million in annual revenue increased from 7 in FY20 to 32 in FY26. At the same time, PCPM, or productivity per medical representative, improved from ₹5.4 lakh to ₹7.0 lakh per month between FY24 and FY26. These metrics indicate that Emcure is trying to grow its existing franchise more efficiently rather than relying only on increasing the size of its sales force.
R&D Could Change the Margin Equation
The other side of operating leverage is higher investment. Emcure spent ₹90 crore on R&D in Q1 FY27, equivalent to 3.5% of revenue, and management expects R&D spending to increase during the rest of FY27.
The company is focusing on biologics, complex injectables, novel drug-delivery systems, long-acting injectables and antibody-drug conjugates, with differentiated products forming a central part of its international strategy.
This creates an important trade-off. Higher R&D expenditure can weigh on margins in the near term, but successful product approvals and commercial launches could create higher-value revenue streams over time. Emcure received 15-plus product approvals across developed and emerging markets in Q1 FY27, providing additional scope for future launches.
Can Margin Expansion Continue?
Management remains confident about the earnings trajectory. It has reiterated expectations for low-to-mid-teen revenue growth in FY27 and indicated that it remains committed to 70–100 basis points of EBITDA-margin expansion.
At the same time, the company is simplifying its structure and expanding its differentiated portfolio. In Q1 FY27, Emcure acquired the remaining 12.05% stake in Gennova, making it a wholly owned subsidiary and giving Emcure full control over its biological platform.
Conclusion
Emcure’s earnings are growing faster than revenue because several factors are working together: operating leverage, better productivity, scale in international markets and stronger execution across its portfolio. Between FY24 and FY26, revenue grew at a 17.6% CAGR while PAT grew at 33.6%, with PAT margin rising to 10.2%. Q1 FY27 has strengthened the trend, with revenue growth of 22.8%, EBITDA growth of 25.8% and reported PAT growth of 36.2%.
The next test, however, is whether Emcure can sustain margin expansion while international sales remain a larger part of the mix and R&D investment increases. The answer will depend on the company’s ability to convert its growing portfolio, stronger sales-force productivity and differentiated R&D pipeline into higher-value revenue without allowing investment requirements to erode the operating leverage achieved so far.